Advice

following a full submission:  

ixekizumab (Taltz®) is accepted for restricted use within NHS Scotland.

Indication under review: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.

Ixekizumab was superior to placebo and to a tumour necrosis factor (TNF) antagonist for improving symptoms of adults with moderate to severe plaque psoriasis.  

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ixekizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

 

 

Download detailed advice262KB (PDF)

Download

Medicine details

Medicine name:
ixekizumab (Taltz)
SMC ID:
1223/17
Indication:
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Skin
Submission type
Full
Status
Restricted
Date advice published
10 April 2017